Low-dose primaquine for falciparum malaria

The Lancet Infectious Diseases

Volumn 14, Issue 6, 2014, Pages 449-

  Meltzer, Eyal ^a   Schwartz, Eli ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; PRIMAQUINE; ANTIMALARIAL AGENT;

CHILDHOOD DISEASE; DRUG EFFICACY; DRUG POTENCY; ETHNIC DIFFERENCE; HUMAN; LETTER; LOW DRUG DOSE; MALARIA CONTROL; MALARIA FALCIPARUM; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; FEMALE; MALE; NOTE;

ANTIMALARIALS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; PRIMAQUINE;

EID: 84900841686     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70773-X     Document Type: Letter

References (4)

1. Eziefula AC, Bousema T, Yeung S, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 2014, 14:130-139.
2. Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013, 369:1381-1382.
3. Wright GE, Niehaus DJ, Drogemoller BI, Koen L, Gaedigk A, Warnich L Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010, 74:340-350.
4. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007, 17:93-101.